固定吸入一氧化二氮/氧气混合气体用于成人癌症爆发痛镇痛的随机对照试验研究方案
本研究为在宁夏医科大学总医院开展的随机、安慰剂对照、双盲试验,计划纳入240例接受常规阿片类药物治疗但仍出现爆发痛的住院癌症患者,按3:1随机分配至三个治疗组和一个对照组,评估固定吸入一氧化二氮/氧气混合气体在治疗5分钟、15分钟及治疗后5分钟的镇痛有效率、安全性和满意度。
要点
- 计划纳入240例成人住院癌症爆发痛患者,随机分为治疗组与对照组(3:1)。
- 治疗组接受口服即释吗啡加一氧化二氮/氧气混合气体,对照组接受口服即释吗啡加氧气。
- 主要终点为治疗5分钟、15分钟及治疗后5分钟疼痛缓解的患者百分比。
核心结论
- 本研究旨在为癌症爆发痛提供一种快速缓解的有效且实用的干预措施,并显著改善患者生活质量。
- 研究采用随机、双盲、安慰剂对照设计以验证疗效,可能为控制爆发痛发作提供新方法。
研究设计与样本
- 随机、安慰剂对照、双盲研究,在宁夏医科大学总医院开展。
- 研究对象为至少18岁、正在接受常规阿片类药物控制癌痛但仍出现爆发痛的住院癌症患者。
- 计划招募240例患者,按3:1随机分配至三个治疗组(A、B、C)和一个对照组(D)。
- 所有治疗组接受标准镇痛治疗(口服即释吗啡)加预先配制的一氧化二氮/氧气混合气体,对照组接受标准镇痛治疗加氧气。
- 患者、医生、护士和数据收集者均对分组设盲。
主要发现
- 评估时间点为治疗前(T0)、治疗中5分钟(T1)和15分钟(T2)、治疗后5分钟(T3)。
- 主要终点为T1、T2、T3时疼痛缓解的患者百分比。
- 次要结局包括治疗安全性、不良事件以及医护人员和患者的满意度。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The management of breakthrough pain in cancer patients is always a challenge for medical professions. Occurring in 80% of cancer patients with advanced disease, breakthrough pain significantly decreases both patient's and caregiver's quality of life. The aim of this study is to assess the analgesic efficacy of a fixed inhaled nitrous oxide/oxygen mixture for adult cancer patients with breakthrough pain. METHODS/DESIGN: This is a randomized, placebo-controlled, double-blind study; it will be conducted in the General Hospital of Ningxia Medical University. The target study subjects are at least 18 years old, and are hospitalized cancer patients who are receiving routine opioids to control cancer-related pain but still experience breakthrough pain. A total of 240 patients will be recruited and randomly allocated between three treatment groups (A, B, C) and a control group (group D) in a ratio of 3:1. All treatment groups (A, B, C) will receive standard pain treatment (oral immediate-release morphine) plus a pre-prepared nitrous oxide/oxygen mixture, and the control group (D) will receive the standard pain treatment plus oxygen. Patients, doctors, nurses, and data collectors are all blind to the experiment. Assessments will be taken before treatment (T0), at 5 min (T1) and 15 min (T2) during treatment, and at 5 min after treatment (T3). The primary endpoint measures will be the percentage of patients whose pain is relieved at T1, T2, and T3. Secondary outcome measures will include the safety of treatment, adverse events, and satisfaction from both health professionals and patients. DISCUSSION: This study aims to provide an effective and practical intervention for a fast breakthrough pain relief and to improve cancer patients' quality of life significantly. The Evidence-Based Medicine Working Group claim that a randomized, double-blind, placebo-controlled experimental intervention is the most appropriate design to demonstrate its efficacy, so this study could give a new approach to controlling breakthrough pain episodes. TRIAL REGISTRATION: ChiCTR-INC-16008075 . Registered on 8 March 2016.
引用
- Liu Q, Wang Y, Luo XJ, et al. A fixed inhaled nitrous oxide/oxygen mixture as an analgesic for adult cancer patients with breakthrough pain: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28077162. doi:10.1186/s13063-016-1739-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。